What Mediated Pioglitazone's Cardiovascular (CV) Benefit in the IRIS Trial?
INZUCCHI S, VISCOLI C, YOUNG L, GORMAN M, CONWIT R, SCHWARTZ G, KERNAN W. What Mediated Pioglitazone's Cardiovascular (CV) Benefit in the IRIS Trial? Diabetes 2018, 67 DOI: 10.2337/db18-17-lb.Peer-Reviewed Original ResearchTransient ischemic attackDensity lipoprotein cholesterolInsulin resistanceCV benefitsLog HRCardiovascular benefitsLipoprotein cholesterolBlood pressureStroke/transient ischemic attackHigh-sensitivity C-reactive proteinHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolMeasures of IRInsulin Resistance InterventionHomeostatic model assessmentDiastolic blood pressureEffect of pioglitazoneSystolic blood pressureC-reactive proteinFavorable effectBoehringer Ingelheim PharmaceuticalsPIO effectIschemic attackNondiabetic patientsHOMA-IREmpagliflozin Improves Renal Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol, and HbA1c
WANNER C, COOPER M, INZUCCHI S, ZINMAN B, HEHNKE U, EYNATTEN M, KOITKA-WEBER A. Empagliflozin Improves Renal Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol, and HbA1c. Diabetes 2018, 67 DOI: 10.2337/db18-524-p.Peer-Reviewed Original ResearchControl of BPLow-density lipoprotein cholesterolRisk of incidentCV risk factorsBlood pressureBoehringer Ingelheim PharmaceuticalsRenal outcomesLipoprotein cholesterolRisk factorsJanssen PharmaceuticalsConventional CV risk factorsEMPA-REG OUTCOME trialBoehringer Ingelheim GmbHDiastolic blood pressureSystolic blood pressureEli LillyAbbVie IncEMPA groupSanofi GenzymeHazard ratioInhibitor empagliflozinRenoprotective roleTime-dependent covariatesOutcome trialsDohme Corp.